Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10019173HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10019323HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10031044HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10025139HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10020261HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS10040464HBVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TVIS20001928HPVENSG00000120907.18protein_codingADRA1ANoNo148B0ZBD3
P35348
TCGA Plot Options
Drug Information
GeneADRA1A
DrugBank IDDB00320
Drug NameDihydroergotamine
Target IDBE0004863
UniProt IDP25100
Regulation Typeagonist
PubMed IDs22444161; 23815106
CitationsDahlof C, Maassen Van Den Brink A: Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache. 2012 Apr;52(4):707-14. doi: 10.1111/j.1526-4610.2012.02124.x. Epub 2012 Mar 22.@@Ramirez Rosas MB, Labruijere S, Villalon CM, Maassen Vandenbrink A: Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin Pharmacother. 2013 Aug;14(12):1599-610. doi: 10.1517/14656566.2013.806487. Epub 2013 Jul 2.
GroupsApproved; Investigational
Direct ClassificationErgotamines, dihydroergotamines, and derivatives
SMILES[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Pathways
PharmGKBPA164743028
ChEMBLCHEMBL1732